News & media

Latest news

We are pleased to share our exciting DCP schedule for 2021

31 March 2021
Here at Adalvo we are committed to being always on target with the aim of achieving great results for our partners and patients.

Adalvo announces ready-to-file dossier completion on Pomalidomide hard capsules development

23 March 2021
Adalvo is delighted to announce the completion of an eCTD format dossier on our Pomalidomide hard capsules development.

Adalvo announces successful Pivotal BE trial on Teriflunomide development

18 January 2021
Adalvo is happy to claim positive pivotal PK result on its Teriflunomide development which will soon be a new addition to our high-value product portfolio to our customers.

Adalvo announces successful pivotal BE trial outcome of Drospirenone + Estradiol program

04 January 2021
We are happy to announce a positive pivotal PK outcome of our Drospirenone + Estradiol development which is our new milestone in creating Adalvo’s mission for a boutique portfolio containing complex and niche products. Adalvo is the only known developer of this asset which underpins our differentiated portfolio strategy

Are you feeling the holiday buzz?

14 December 2020
As the Holidays are rapidly approaching, we really wanted to take this opportunity to thank you all for your wonderful collaboration and support in what has undoubtedly been a truly outstanding and remarkable year for all us on pretty much every front.

Adalvo wins Business Development of the Year award at the annual Global Generics Awards

05 November 2020
The Adalvo team have certainly been busy bees this year, driven by their passion for relentless commitment to customers and business partners. Adalvo has been a true success story ever since Alvogen and Alvotech introduced the new B2B corporate identity early this year.

Adalvo announces completion on BE trials of Solifenacin + Tamsulosin development

30 October 2020
Adalvo is happy to announce that in addition to our earlier reported studies we successfully closed our last bioequivalence trial that was conducted in steady state dosing.

Alvotech and Teva announce strategic partnership to collaborate in the U.S. biosimilar market

05 August 2020
Alvotech and Teva bring together highly complementary capabilities to secure a leading position in the U.S. biosimilar market. The collaboration is one of the broadest partnerships within the U.S. biosimilar industry to date to accelerate improved patient access for high quality biosimilar medicines in the U.S. biosimilar industry.

Adalvo and Ambiopharm partner on development & licensing for key peptide products

29 July 2020
Adalvo today announced that it has entered into partnership with AmbioPharm, a US-based pharmaceutical company, for an exclusive collaboration on the co-development and licensing for the commercialization of several complex pharmaceutical products in key global markets.

Adalvo announces successful dual pivotal BE trial outcome of Solifenacin + Tamsulosin development

21 July 2020
Adalvo is delighted to announce successful Fed and Fast Pivotal BE outcome of its Solifenacin + Tamsulosin development which demonstrates Adalvo's ability to continuously offer first-to-market opportunities to its valued partners.

Adalvo submits generic dossier applications for Icatibant pre-filled syringe

16 July 2020
Adalvo today announces that it has submitted filings for generic dossier applications with the European Medicines Agency, seeking approval to market an Icatibant pre-filled syringe. Based on available information, Adalvo believes it is in the first wave of applicants to submit its filing within the European Union.

Adalvo announces positive CHMP opinion for Livogivatm (Teriparatide injection)

29 June 2020
New commercialization agreement in Latin America announced with a large, multinational pharmaceutical firm.

Adalvo announces new strategic partnerships with Alvogen subsidiary

11 May 2020
Adalvo, the new B2B company as part of the Alvogen and Alvotech family, have worked with Lotus pharmaceuticals in Asia to announce 10 new strategic partnership agreements in 2020 with some of the world’s leading pharmaceutical companies.

Adalvo looking to create a buzz following its launch

05 May 2020
Global pharmaceutical companies Alvogen and Alvotech have introduced a new corporate identity for its B2B operations – called Adalvo – following rapid growth in this area of business in the past few years.

Message regarding Covid-19

26 March 2020
We are living through a very challenging time. The Coronavirus spread is causing changes in everyday life and we are constantly monitoring the situation here at Adalvo

Alvotech and DKSH partner to bring key biosimilar to Asia

24 March 2020
Alvotech Hf and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced that Alvotech Hf and DKSH have entered into an exclusive license partnership for the commercialization of AVT02, an adalimumab biosimilar, in selected APAC markets.

Alvogen submits European application for generic Pazopanib

24 March 2020
Alvogen today announced that it has submitted generic dossier applications for Pazopanib tablets.

Successful Kick Off meeting in Zurich

22 March 2020
This February the Adalvo team got together in Zurich, Switzerland for a Kick Off meeting.

Brand Assets

Adalvo logo, white on red

Adalvo logo, red on white

Adalvo logo, dark grey

Media Contact

Elisabet Hjaltadottir
Corporate Marketing & Communication